Elite Pharmaceuticals, Inc.

OTCPK:ELTP Stock Report

Market Cap: US$534.1m

Elite Pharmaceuticals Management

Management criteria checks 3/4

Elite Pharmaceuticals' CEO is Nasrat Hakim, appointed in Aug 2013, has a tenure of 11.42 years. directly owns 20.74% of the company’s shares, worth $110.79M. The average tenure of the management team and the board of directors is 10.8 years and 13.3 years respectively.

Key information

Nasrat Hakim

Chief executive officer

US$1.1m

Total compensation

CEO salary percentagen/a
CEO tenure11.4yrs
CEO ownership20.7%
Management average tenure10.8yrs
Board average tenure13.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nasrat Hakim's remuneration changed compared to Elite Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

US$20m

Mar 31 2024US$1mn/a

US$20m

Dec 31 2023n/an/a

US$16m

Sep 30 2023n/an/a

US$18m

Jun 30 2023n/an/a

US$4m

Mar 31 2023US$1mUS$500k

US$4m

Dec 31 2022n/an/a

US$7m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

US$7m

Mar 31 2022US$1mUS$500k

US$9m

Dec 31 2021n/an/a

US$6m

Sep 30 2021n/an/a

US$6m

Jun 30 2021n/an/a

US$6m

Mar 31 2021US$1mUS$500k

US$5m

Dec 31 2020n/an/a

US$7m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

-US$1m

Mar 31 2020US$1mUS$500k

-US$2m

Dec 31 2019n/an/a

-US$6m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019US$1mUS$500k

-US$9m

Dec 31 2018n/an/a

-US$9m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$3m

Mar 31 2018US$1mUS$500k

-US$4m

Compensation vs Market: Nasrat's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Nasrat's compensation has increased whilst the company is unprofitable.


CEO

Nasrat Hakim (63 yo)

11.4yrs

Tenure

US$1,078,000

Compensation

Mr. Nasrat Hakim has been the Chief Executive Officer and President of Elite Pharmaceuticals, Inc. since August 1, 2013. Mr. Hakim has pharmaceutical and medical industry experience in Quality Assurance, A...


Leadership Team

NamePositionTenureCompensationOwnership
Nasrat Hakim
Chairman11.4yrsUS$1.08m20.74%
$ 110.8m
Carter Ward
Chief Financial Officer1.3yrsUS$532.04k0.47%
$ 2.5m
Douglas Plassche
Executive Vice President of Operations11.4yrsUS$652.47k0%
$ 0
Dianne Will
Vice President of Investor Relations & Corporate Affairs12yrsno datano data
George Smith
Vice President of Legal10.3yrsUS$412.00kno data
Kirko Kirkov
Chief Commercial Officer2.3yrsUS$282.20kno data

10.8yrs

Average Tenure

60yo

Average Age

Experienced Management: ELTP's management team is seasoned and experienced (10.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nasrat Hakim
Chairman11.4yrsUS$1.08m20.74%
$ 110.8m
Jeffrey Whitnell
Independent Director15.3yrsUS$30.00k0.30%
$ 1.6m
Barry Dash
Independent Director19.8yrsUS$30.00k0.30%
$ 1.6m
Davis Caskey
Independent Director8.8yrsUS$30.00k0.19%
$ 1.0m

13.3yrs

Average Tenure

72yo

Average Age

Experienced Board: ELTP's board of directors are seasoned and experienced ( 13.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 22:39
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Elite Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Masashi MoriCredit Suisse